These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36983191)

  • 21. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
    Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
    Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
    Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dupilumab in patients with atopic dermatitis: assessing treatment response, clinical features and potential biomarkers in real-life.
    Limão R; Brás R; Pedro E; Silva SL; Lopes A
    Eur Ann Allergy Clin Immunol; 2024 Apr; ():. PubMed ID: 38591168
    [No Abstract]   [Full Text] [Related]  

  • 25. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
    Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Sirna R; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavò SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Savi E; Stingeni L; Romano A; Argenziano G;
    J Dermatolog Treat; 2021 Aug; 32(5):507-513. PubMed ID: 31647347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atopic dermatitis, extrinsic atopic dermatitis and the hygiene hypothesis: results from a cross-sectional study.
    Zutavern A; Hirsch T; Leupold W; Weiland S; Keil U; von Mutius E
    Clin Exp Allergy; 2005 Oct; 35(10):1301-8. PubMed ID: 16238789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dupilumab in the Treatment of Cheilitis in Atopic Dermatitis Patients.
    Shan J; Ali K; Da J; Li M; Qiu Y; Lou H; Wu L
    Clin Cosmet Investig Dermatol; 2022; 15():2437-2443. PubMed ID: 36387959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dupilumab modulates specific IgE mite responses at the molecular level in severe T2-high atopic dermatitis: A real-world experience.
    González-Pérez R; Poza-Guedes P; Mederos-Luis E; Sánchez-Machín I
    Front Med (Lausanne); 2022; 9():939598. PubMed ID: 36035412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.
    Blauvelt A; Simpson EL; Tyring SK; Purcell LA; Shumel B; Petro CD; Akinlade B; Gadkari A; Eckert L; Graham NMH; Pirozzi G; Evans R
    J Am Acad Dermatol; 2019 Jan; 80(1):158-167.e1. PubMed ID: 30092324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry.
    Kojanova M; Tanczosova M; Strosova D; Cetkovska P; Fialova J; Dolezal T; Machovcova A; Gkalpakiotis S;
    J Dermatolog Treat; 2022 Aug; 33(5):2578-2586. PubMed ID: 35170381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.
    Napolitano M; Fabbrocini G; Neri I; Stingeni L; Boccaletti V; Piccolo V; Amoruso GF; Malara G; De Pasquale R; Di Brizzi EV; Diluvio L; Bianchi L; Chiricozzi A; Di Guida A; Del Duca E; Moschese V; Di Lernia V; Dragoni F; Gruber M; Hansel K; Licari A; Manti S; Leonardi S; Mastorino L; Ortoncelli M; Provenzano E; Palermo A; Patella V; Peduto T; Pezzolo E; Piras V; Potestio L; Battista T; Satta R; Termine S; Palma P; Zangari P; Patruno C
    Paediatr Drugs; 2022 Nov; 24(6):671-678. PubMed ID: 36028611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis.
    Howell MD; Novak N; Bieber T; Pastore S; Girolomoni G; Boguniewicz M; Streib J; Wong C; Gallo RL; Leung DY
    J Invest Dermatol; 2005 Oct; 125(4):738-45. PubMed ID: 16185274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
    Paller AS; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Gonzalez ME; Lockshin B; Chen Z; Bansal A; Levit NA; Prescilla R
    Paediatr Drugs; 2023 Jan; 25(1):67-77. PubMed ID: 36529811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience.
    Ferrucci S; Casazza G; Angileri L; Tavecchio S; Germiniasi F; Berti E; Marzano AV; Genovese G
    J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32183179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease.
    Ferrucci S; Angileri L; Tavecchio S; Fumagalli S; Iurlo A; Cattaneo D; Marzano AV; Maronese CA
    J Dermatolog Treat; 2022 Aug; 33(5):2587-2592. PubMed ID: 35261333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-, mid- and long-term efficacy of dupilumab in moderate to severe atopic dermatitis: a real life multicenter Italian study on 2576 patients.
    Ferrucci S; Tavecchio S; Maronese CA; Balato A; Di Brizzi E; Ortoncelli M; Ribero S; Girolomoni G; Maurelli M; Belloni Fortina A; Caroppo F; Naldi L; Pezzolo E; Nettis E; Pugliese F; Stingeni L; Hansel K; Rubegni G; Calabrese L; Russo F; Gola M; Magnaterra E; Rongioletti F; Mercuri SR; Paolino G; Savoia P; Veronese F; Foti C; Ambrogio F; Scalvenzi M; Napolitano M; Patruno C; Dastoli S; Corazza M; Borghi A; Calzavara-Pinton PG; Rossi M; Offidani A; Radi G; Bonzano L; Ferreli C; Piras V; Satta R; Sucato F; Malagoli P; Gaiani F; Micali G; Musumeci ML; Fargnoli MC; Esposito M; Grieco T; Chello C; Casazza G; Marzano A
    Clin Exp Dermatol; 2024 Jun; ():. PubMed ID: 38860563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dupilumab treatment decreases MBC2s, correlating with reduced IgE levels in pediatric atopic dermatitis.
    Starrenburg ME; Bel Imam M; Lopez JF; Buergi L; Nguyen NT; Nouwen AEM; Arends NJT; Caspers PJ; Akdis M; Pasmans SGMA; van de Veen W
    J Allergy Clin Immunol; 2024 Nov; 154(5):1333-1338.e4. PubMed ID: 39038586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association between eosinophils (CD16
    Čelakovská J; Čermáková E; Boudková P; Andrýs C; Krejsek J
    Dermatol Ther (Heidelb); 2023 May; 13(5):1193-1210. PubMed ID: 37071375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.